Implementation of Pharmacogenomic Sample Collection in Clinical Trials
نویسندگان
چکیده
This chapter is intended to provide an overview of the operational considerations and potential obstacles that can be anticipated during the implementation of pharmacogenomic research in clinical trials. Particular attention is given to the elements of the protocol and of the informed consent and the considerations for collection of different sample types on a global level. The goal is to provide the reader with an appreciation for the study design elements on an operational level rather than on a scientific or statistical study design level. Educational efforts by various working groups to harmonize global standards are also outlined and will provide the reader with an overview of the ongoing efforts to promote global genomic research in the present day.
منابع مشابه
Characteristics of Clinical Trials in Iran: A Sample of 5000 Trials Registered in IRCT
Background and Objectives: A considerable number of clinical trials are conducted in Iran each year. Not much is known about the characteristics of them, this study aimed to investigate key characteristics of Iranian clinical trials. Methods: All clinical trial protocols registered in IRCT until November 2013 were selected. Text mining techniques were used to extract information from data t...
متن کاملThe clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes
Prescribing safe and effective medications is a challenge in psychiatry. While clinical use of pharmacogenomic testing for individual genes has provided some clinical benefit, it has largely failed to show clinical utility. However, pharmacogenomic testing that integrates relevant genetic variation from multiple loci for each medication has shown clinical validity, utility and cost savings in m...
متن کاملPharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
Many clinical trials of oncology drugs now include at least a consideration of pharmacogenomics, the study of germline or acquired genetic factors governing a drug's response and toxicity. Besides the potential benefit to patients from the consideration of personalized pharmacogenomic information when making treatment decisions, the incentive is clear for oncology drug developers to incorporate...
متن کاملPharmacogenomic approach in type 2 diabetes treatment
Introduction: Type 2 diabetes (T2D) is chronic health caused by the interaction between genetic and environmental factors that results in high blood glucose. The evidence-based guidelines for diabetes management are mainly based on lifestyle changes, control of risk factors, and the management of blood glucose levels. Although numerous antidiabetic agents have been developed over time, T2D trea...
متن کاملA mixed Bayesian/Frequentist approach in sample size determination problem for clinical trials
In this paper we introduce a stochastic optimization method based ona mixed Bayesian/frequentist approach to a sample size determinationproblem in a clinical trial. The data are assumed to come from a nor-mal distribution for which both the mean and the variance are unknown.In contrast to the usual Bayesian decision theoretic methodology, whichassumes a single decision maker, our method recogni...
متن کامل